2016～2018年中国结直肠癌临床实践指南的质量评价

目的了解我国2016年至2018结直肠癌临床实践指南(CPGs)的现状并采用AGREE-China工具对其质量进行评价,为我国规范制定结直肠癌CPGs提供参考并为临床实践提供明确的推荐意见。方法计算机检索中国知网数据库(CNKI)、万方数据库(Wanfang Data)、维普中文科技期刊数据库(VIP)和中国生物医学文献数据库(CBM)4个中文期刊数据库,搜集我国制定的结直肠癌CPGs,检索时限为2016年1月1日至2018年12月31日。由2位评价员按照纳入与排除标准独立筛选文献和提取资料,采用AGREE-China评价纳入的中国结直肠癌CPGs的质量。结果共纳入10部指南。指南在AGREE-China 5个领域平均得分如下:科学性与严谨性为21.10%,有效性与安全性为5.00%,经济性为6.00%,可用性与可行性为63.97%,利益冲突为0。结论我国结直肠癌CPGs总体质量不高,大部分缺乏循证医学证据。在今后指南制定中要特别注重指南制定的科学性与严谨性、有效性与安全性和经济性,提高对利益冲突的关注,并及时对指南进行更新修订。

Quality assessment of Clinical Practice Guidelines for Colorectal Cancer in China from 2016 to 2018

ObjectiveTo investigate the current situation of Clinical Practice Guidelines (CPGs) on colorectal cancer in China 2016 to 2018, and use the AGREE China tool to evaluate the quality of CPGs, in order to provide reference for clinical practice.MethodsCNKI, Wanfang Data, CBM and VIP databases were searched for clinical practice guidelines for colorectal cancer in China from Jan. 1st of 2016 to Dec. 31st of 2018. Two researchers selected literatures and extracted data according to the inclusion and exclusion criteria independently. The Appraisal of Guidelines for Research and Evaluation China (AGREE China) was utilized to assess the quality of the guidelines.ResultsA total of 10 guidelines were included. The average scores of guidelines in five domains of AGREE China were as follows: scientificity/preciseness 21.10%, effectiveness/safety 5.00%, economy 6.00%, availability/feasibility 63.97%, and conflict of interest is 0.ConclusionsThe overall quality of Chinese colorectal cancer CPGs is not high. Most of them lack evidence based medical evidence. In the future, the scientificity/preciseness, effectiveness/safety and economy should be concentrated as well as the conflict of interest and updating the guidelines in time.